710 reports of this reaction
4.2% of all LAMIVUDINE AND ZIDOVUDINE reports
#2 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #2 most commonly reported adverse reaction for LAMIVUDINE AND ZIDOVUDINE, manufactured by ViiV Healthcare Company. There are 710 FDA adverse event reports linking LAMIVUDINE AND ZIDOVUDINE to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 4.2% of all 16,773 adverse event reports for this drug.
Patients taking LAMIVUDINE AND ZIDOVUDINE who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among LAMIVUDINE AND ZIDOVUDINE users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for LAMIVUDINE AND ZIDOVUDINE:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 710 FDA reports for LAMIVUDINE AND ZIDOVUDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 4.2% of all adverse event reports for LAMIVUDINE AND ZIDOVUDINE, making it one of the most commonly reported side effect.
If you experience foetal exposure during pregnancy while taking LAMIVUDINE AND ZIDOVUDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.